Summary
To study the effects of acute myocardial infarction on the pharmacokinetics of disopyramide a single oral dose of disopyramide base (200 mg) was administered to 6 patients with myocardial infarction both in the acute (Study I) and recovery (Study II) phases. An intravenous tracer dose of14C-disopyramide (2.5 µg/0.3 mg) was given simultaneously with the oral dose. On the basis of the intravenous tracer data, the volume of distribution, binding to plasma proteins, total plasma clearance, renal clearance and elimination half-life of disopyramide and mono-N-dealkyl disopyramide were the same in Studies I and II. The peak serum concentrations of disopyramide after oral dosing in Studies I and II were 2.6±1.2 (SEM) and 6.4±1.9 µg/ml, respectively (p<0.05), the peak times 3.29±1.22 and 1.21±0.39 h (N.S.) and the AUCINF 38.0±7.7 and 60.7±9.9 µg·h·ml−1 (p<0.05). The recovery of disopyramide in urine over 3 days averaged 46% and 47% of dose, and that of mono-N-dealkyl disopyramide 22% and 16% of the dose, respectively. Thus, the gastrointestinal absorption of disopyramide was disturbed, resulting in low plasma concentrations after oral dosing, whereas the elimination of disopyramide was unaltered in the acute phase of myocardial infarction.
Similar content being viewed by others
References
Benowitz NL, Meister W (1976) Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet 1: 389–405
Woosly RL, Shand DG (1978) Pharmacokinetics of antiarrhythmic drugs. Am J Cardiol 41: 986–995
Prescott LF, Pottage A (1978) The importance of pharmacokinetics in the choice of an antiarrhythmic drug. In: Sandoe E, Julian DG, Bell JW, (eds) Management of ventricular tachycardia: role of mexiletine. Excerpta Medica, Amsterdam pp 456–470
Thomson PD, Melom KL, Richardson JA, Colin K, Steinbrunn W, Cudihee R, Rowland M (1973) Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans. Ann Intern Med 78: 499–508
Halkin H, Meffin P, Melmon KL, Row I, Row M (1975) Influence of congestive heart failure in blood levels of lidocaine and its active monodeethylated metabolite. Clin Pharmacol Ther 17: 669–679
Ward JW, Kinghorn GR (1976) The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens. J Int Med Res 4 [Suppl 1]: 49–53
Ilett KF, Madsen BW, Woods JD (1979) Disopyramide kinetics in patients with acute myocardial infarction. Clin Pharmacol Ther 26: 1–7
Jounela AJ, Pentikäinen PJ, Oksanen K (1982) The pharmacokinetics of disopyramide in patients with acute myocardial infarction. Int J Clin Pharmacol Ther Toxicol 20: 276–282
Duchateau AMJA, Merkus FWHM, Schobben F (1975) Rapid gas chromatographic determination of disopyramide in serum using a nitrogen detector. J Chromatogr 109: 432–435
Meffin PJ, Harapat SR, Harrison DC (1977) High-pressure liquid chromatographic analysis of drugs in biological fluids. III. Analysis of disopyramide and its mono-n-dealkylated metabolite in plasma and urine. J Chromatogr 132: 503–510
Gupta EN, Eng F, Lewis D (1979) Fluorescence photometric determination of disopyramide and mono-n-dealkylated disopyramide in plasma after thin-layer chromatography. Anal Chem 51: 455–458
Borgå O, Azarnoff DL, Plym-Forshell G, Sjöqvist F (1969) Plasma protein binding of tricyclic antidepressants in man. Biochem Pharmacol 18: 2135–2144
Kumana CR, Rambihar VS, Willis K, Gupta RN, Tanser PH, Cairns JA, Wildeman RA, Johnston M, Johnson AL, Gent M (1982) Absorption and antidysrhythmic activity of oral disopyramide phosphate after acute myocardial infarction. Br J Clin Pharmacol 14: 529–537
Heel RC, Brogden RN, Speight TM, Avery GS (1978) Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias. Drugs 15: 331–368
Piafsky KM, Sellers EM, Strauss H, Woolner B (1980) Plasma binding of lidocaine, disopyramide and propranolol in acute myocardial infarction (MI). In: Turner P, Padgham C (eds) World Conference on Clinical Pharmacology and Therapeutics. MacMillan Publishers, London, abstract 0346
Cunningham JL, Shen DD, Shudo I, Azarnoff DL (1977) The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet 2: 373–383
Rangno RE, Warnica W, Ogilvie RI, Kreeft J, Bridger E (1976) Correlation of disopyramide pharmacokinetics with efficacy in ventricular tachy-arrhythmia. J Int Med Res 4 [Suppl 1]: 54–58
Koch-Weser J (1971) Pharmacokinetics of procainamide in man. Ann NY Acad Sci 179: 370–382
Hagemeijer F (1975) Absorption, half-life and toxicity of oral aprindine in patients with acute myocardial infarction. Eur J Clin Pharmacol 9: 21–26
Pottage A, Campbell RWF, Achuff SC, Murray A, Julian DG, Prescott LF (1978) The absorption of oral mexiletine in coronary care patients. Eur J Clin Pharmacol 13: 393–399
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pentikäinen, P.J., Huikuri, H., Jounela, A.J. et al. Disopyramide pharmacokinetics in patients with acute myocardial infarction. Eur J Clin Pharmacol 28, 45–51 (1985). https://doi.org/10.1007/BF00635707
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00635707